Unither Pharmaceuticals’ Co-Development program is an exclusive opportunity, designed to support pharmaceutical companies, startups, biotechs, and other innovative healthcare players in the development of innovative solutions, while sharing risks and investments.
An innovative partnership to reduce time-to-market for your products
A unique model based on collaboration
Co-development is a flexible and tailor-made partnership:
- Development costs shared with Unither Pharmaceuticals, according to the agreed scope and responsibilities.
- Intellectual property is fully retained by the project owner.
- Collaboration terms are defined according to objectives and commercial potential.
This approach allows you to reduce time-to-market, optimize costs, and benefit from comprehensive support, from design to commercialization.
How does the partnership work?
Collaboration
The level of participation and the terms of the partnership are defined based on several criteria:
- The product’s therapeutic and commercial potential
- The financial and technical needs identified
- The targeted distribution markets and territories
Unither’s compensation can take several forms, as defined by contract:
- Distribution rights in certain markets
- Manufacturing exclusivity or priority
- Percentage of licensing revenue
- Percentage of sales revenue
Benefits of the Unither Co-Development partnership
|
✓ Development & manufacturing expertise on 4 continents |
Access to Unither’s expertise in development and production across 4 continents |
|
✓ Improved time-to-market |
By adopting a “one-stop-shop” approach that covers the entire value chain: from ideation to industrial production, we guarantee controlled timelines and project continuity. This organization draws on simplified inter-site transfers, an anticipation of industrial constraints, shared financing models, and the support of a global network of partners. |
|
✓ Risk and benefit sharing |
Our model is based on pooled resources and investments, combined with value-sharing schemes such as the granting of distribution rights per territory, payment of royalties, or participation in commercialization revenues. |
|
✓ Access to an international network |
Expanded distribution to multiple territories – combined with the effects of volume linked to market expansion – helps to reduce product costs. |
|
✓ Intellectual property retained |
If the product is protected by intellectual property rights belonging to the client, the client remains the sole and unique owner. |
FAQ - co-development program
Do I retain ownership of the intellectual property rights to my product in the context of co-development with Unither?
Yes. The intellectual property remains fully owned by the project leader. Unither does not acquire any rights to your patents,dossiers, formulas, or scientific data. We work with you as a co-development partner — sharing investments, expertise, and risks — but you remain the sole owner of your IP. The terms of collaboration (royalties, distribution rights, manufacturing exclusivity, etc.) are contractually defined and have no impact on the ownership of your intellectual property.
What partnership models does Unither offer (co-development, out-licensing, milestones, royalties, etc.)?
Our partnership models include territorial distribution rights, manufacturing exclusivity, or a percentage of licensing revenue.
Is co-development only for drug development?
No. The program is also open to medical devices or combined products, depending on the project.
Who decides if a project is eligible for the Unither Co-Development program?
Each project is evaluated by an in-house committee composed of experts in Development, Industry, Quality, Regulations, and Business Development. This committee analyzes the product’s scientific, therapeutic, and commercial potential, as well as its technical and industrial feasibility at our sites. Criteria include medical needs, scientific robustness, regulatory requirements, market strategy, required investment, and the potential for sharing risks and value with our partner.